GLUE Projected Dividend Yield
Monte Rosa Therapeutics Inc ( NASDAQ : GLUE )Monte Rosa Therapeutics is a biopharmaceutical company. Co. has developed a protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), to enable its target-centric approach to its molecular glue degraders (MGDs) discovery and development. Co.'s QuEEN platform enables it to identify protein targets and associated MGD product candidates that are designed to eliminate therapeutically-relevant proteins. Co.'s primary candidate, MRT-2359, is an orally bioavailable degrader of the translation termination factor protein GSPT1 in development initially for use in the treatment of cancers overexpressing one of the Myc family genes (c-Myc, N-Myc and L-Myc). 20 YEAR PERFORMANCE RESULTS |
GLUE Dividend History Detail GLUE Dividend News GLUE Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |